Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Candel Therapeutics

< Previous 1 2 Next >
Candel Therapeutics Announces $80 Million Proposed Public Offering
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Join Russell 3000® Index
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.